Genmab FRα ADC Succeeds in Global Late-Stage Ovarian Cancer Trial, Cutting Death Risk 57% in ITT Population

Genmab's FRα ADC succeeded in a global late-stage ovarian cancer trial, reducing the risk of death by 57% in the ITT population. In the PAS population, the risk of death fell by 56%. Genmab's share price rose 9.5% on the day, bringing its market cap to $27.3 billion.